A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 μg BID or 40 microg BID for 12 Weeks in Patients Aged 4 to less than 12 Years With Persistent Asthma.
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Ciclesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Sanofi
- 04 Nov 2006 New trial record.